Yes, that makes sense. Merck and Ariad will likely go with a name that limits the branding to sarcoma, even though it will likely make more money in the combinations in indications such as prostate, endometrial, and lung cancers.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.